![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ims Health Holdings, Inc. | NYSE:IMS | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 31.34 | 0 | 01:00:00 |
Up to 15 Percent of Healthcare System Costs Avoidable; Effective Patient Activation by Multiple Stakeholders Key to Driving Improvement
Despite improved diagnosis and advances in treatment options for individuals with Type 2 Diabetes, sub-optimal therapy adherence and persistence result in significant economic and societal burden as well as avoidable patient complications in six diverse healthcare systems around the world, according to a new report series issued today by the IMS Institute for Healthcare Informatics. Disease complications account for an estimated 61 – 80 percent of Type 2 Diabetes-related costs in the countries studied, with 4 – 15 percent of costs linked to poor adherence and persistence. Effective patient activation—how well people understand their role in the care process along with their ability and willingness to actively manage their own health and care—is key to deriving greater value from existing diabetes treatments.
The report series—Improving Type 2 Diabetes Therapy Adherence and Persistence: How to Address Avoidable Economic and Societal Burden—analyzes the unique epidemiology, local healthcare dynamics and drivers for adherence and persistence in Brazil, Germany, the Kingdom of Saudi Arabia, Mexico, the U.K. and the U.S. Avoidable Type 2 Diabetes costs due to diabetes-related complications were determined using IMS Health’s CORE Diabetes Model, a validated, peer-reviewed algorithm that simulates clinical outcomes and costs for cohorts of people with the condition.
The reports highlight a number of practical, actionable recommendations to raise levels of adherence and persistence in Type 2 Diabetes therapies that span diet, exercise and use of glucose-lowering medicines. They include identifying and profiling patients in need of help; improving access to customized education materials; maximizing engagement between healthcare providers and patients; and using digital technology to maintain effective disease self management.
“The rising prevalence of Type 2 Diabetes and its associated complications is the root of considerable strain on society and an economic burden on healthcare systems,” said Murray Aitken, IMS Health senior vice president and executive director of the IMS Institute for Healthcare Informatics. “Simple, customized interventions that put patients on the path to optimal adherence and persistence can yield tangible results, but require alignment between healthcare and government leaders, as well as the active involvement of voluntary associations and the private sector.”
Key findings of the report series include the following:
The report series, including a detailed description of methodologies, are available at www.theimsinstitute.org. This study is based on research and analysis undertaken by the IMS Consulting Group with support from Lilly Diabetes.
About the IMS Institute for Healthcare Informatics
The IMS Institute for Healthcare Informatics provides key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. It is a research-driven entity with a worldwide reach that collaborates with external healthcare experts from across academia and the public and private sectors to objectively apply IMS Health’s proprietary global information and analytical assets. More information about the IMS Institute can be found at: http://www.theimsinstitute.org.
About IMS Health
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. Our 7,000 services experts connect configurable SaaS applications to 15+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160712005431/en/
IMS HealthTor Constantino, +1-484-567-6732tconstantino@us.imshealth.com
1 Year IMS HEALTH HOLDINGS, INC. Chart |
1 Month IMS HEALTH HOLDINGS, INC. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions